A legal challenge by authors over three retracted articles about mifepristone is set for an arbitration conference this month as nationwide debate over the abortion pill heats up at the appellate level.
Ten researchers sued Sage in 2024 after the publisher retracted three of their papers about the purported dangers of mifepristone, a medication that ends early pregnancy. The authors alleged the company “applied inconsistent retraction standards” to their work based on Sage’s perception of their “pro-life affiliations,” in violation of California’s anti-discrimination law, according to their complaint.
The authors asked the Superior Court of California, County of Ventura to compel Sage into arbitration, as required by publishing agreements the researchers signed with the company. Arbitration is an alternative pathway for resolving disputes in which an arbitrator hears the parties’ arguments and issues a decision outside of the traditional court process.
The retraction notice for the articles, which were published in Health Services Research and Managerial Epidemiology from 2019 to 2022, stated the publisher removed them because of undeclared conflicts of interest by the authors. According to the notice, all but one of the article’s authors were affiliated with one or more pro-life advocacy organizations, “despite having declared they had no conflicts of interest when they submitted the article for publication or in the article itself.”
Further investigation by subject matter experts also found “fundamental problems with the study design and methodology” of two of the articles, and “unsupported assumptions and misleading” findings in the third article, according to the notice.
A federal judge in Texas cited two of the articles in his 2023 decision to temporarily suspend mifepristone. The U.S. Supreme Court ultimately rejected the suspension, allowing the medication to remain accessible while lawsuits in the lower courts continue.
One of those disputes is a current challenge by Louisiana against a rule from the U.S. Food and Drug Administration allowing doctors to prescribe mifepristone through telehealth and patients to receive it through the mail. State officials argue mifepristone should be available only in-person. A three-judge panel of the 5th U.S. Circuit Court of Appeals heard arguments in the case on Sept. 9.
In its complaint, Louisiana cites several studies about the risks of mifepristone, including a 2024 paper by James Studnicki, lead author of the three retracted papers, about emergency department visits following medication abortions among women in the Medicaid program. The three retracted articles are not referenced in the state’s complaint.
In court documents, the FDA attorneys stated the agency is conducting its own study of statistical data and safety outcomes about the medication. They also called the court challenge a “waste of judicial resources” while the agency’s review is ongoing and emphasized that Louisiana remains free to enforce its own state abortion restrictions.
The three retracted papers included articles about emergency room visits by women who use mifepristone, characteristics of physicians who perform abortions, and complications from chemical abortions, which now account for nearly two-thirds of all abortions in this country.
Over the last two years, the legal challenge by the authors has stalled while the plaintiffs and Sage sparred over choosing an arbitrator. Sage accused the researchers of attempting to exclude Sage from the arbitrator selection process. After several rounds of delays, the parties are scheduled for a status conference about the arbitration on Sept. 21, according to court records.
Studnicki previously told Retraction Watch the retractions were “a blatant attempt to discredit excellent research which is incongruent with a preferred abortion narrative.” The publisher removed Studnicki from the journal’s editorial board in the aftermath of its investigation. Studnicki, vice president and director of data analytics at the pro-life Charlotte Lozier Institute, told us he had no comment about the case until a final decision is reached.
Camille Gamboa, a spokesperson for Sage, told us the publisher had “no information to share at this time while the case is ongoing.”
Like Retraction Watch? You can make a tax-deductible contribution to support our work, follow us on X or Bluesky, like us on Facebook, follow us on LinkedIn, add us to your RSS reader, or subscribe to our daily digest. If you find a retraction that’s not in our database, you can let us know here. For comments or feedback, email us at [email protected].
Facts Only
* Ten researchers sued publisher Sage in 2024.
* The lawsuit concerns the retraction of three papers regarding mifepristone.
* The papers were published in Health Services Research and Managerial Epidemiology between 2019 and 2022.
* Sage retracted the papers citing undeclared conflicts of interest and methodological flaws.
* The authors allege the retractions violated California’s anti-discrimination law based on their pro-life affiliations.
* The authors requested the Superior Court of California, County of Ventura, to compel arbitration.
* A status conference regarding the arbitration is scheduled for September 21.
* A federal judge in Texas cited two of the retracted papers in a 2023 decision to temporarily suspend mifepristone.
* The U.S. Supreme Court later rejected that suspension.
* Louisiana is currently challenging FDA rules regarding telehealth prescriptions of mifepristone in the 5th U.S. Circuit Court of Appeals.
* James Studnicki is the lead author of the retracted papers and a director at the Charlotte Lozier Institute.
Executive Summary
A legal dispute has emerged between ten researchers and the publisher Sage over the retraction of three studies concerning the safety and outcomes of mifepristone. Sage maintains that the retractions were necessary due to the authors' failure to disclose affiliations with pro-life advocacy organizations and significant flaws in study design and methodology. Conversely, the authors claim the publisher applied inconsistent standards driven by bias against their political and religious affiliations, alleging a violation of California anti-discrimination laws.
The conflict is situated within a broader, high-stakes legal battle over the accessibility of the abortion pill. While the U.S. Supreme Court has allowed mifepristone to remain available, lower court challenges—such as a current suit by Louisiana regarding telehealth prescriptions—continue. The retracted research previously influenced judicial decisions, adding a layer of systemic complexity to the debate over scientific integrity and political neutrality in medical publishing. The parties are currently moving toward arbitration to resolve the dispute.
Full Take
The strongest version of this narrative is a clash between two fundamental pillars of academic integrity: the requirement for full disclosure of conflicts of interest to ensure objectivity, and the protection of researchers from ideological discrimination. It presents a scenario where scientific gatekeeping is accused of becoming a political tool, while the publisher argues it is merely enforcing rigorous standards against biased data.
This situation reflects a broader pattern of "weaponized scholarship," where academic papers are produced not for peer-reviewed advancement, but as evidentiary ammunition for litigation. When a federal judge cites specific studies to suspend a medication, the stakes of a retraction shift from academic reputation to national policy. The root cause is the collapse of a neutral "scientific consensus" in the face of extreme polarization; data is no longer viewed as objective but as a proxy for the ideology of the author.
The implications suggest a future where the "provenance" of a study—who funded it and what they believe—may be scrutinized more than the data itself. This risks creating parallel scientific ecosystems where research is validated not by methodology, but by political alignment.
Patterns detected: none
Bridge Questions: If a study is methodologically flawed but its authors had no political affiliations, would it have been retracted? How does the use of academic papers in judicial proceedings change the incentive structure for researchers?
Counterstrike Scan: A coordinated campaign would likely frame this as a "censorship" narrative to delegitimize the peer-review process entirely or use it to paint all opposing medical data as fraudulent. The current content does not match this pattern; it reports on the legal proceedings and the stated justifications of both parties without adopting a crusade-like tone.
Sentinel — Human
The text appears to be a factual summary of an unfolding legal dispute, exhibiting the characteristics of journalistic reporting rather than purely synthetic generation.